Lynda Charters

Alkeus Pharmaceuticals has dosed the first participant in the phase 3 NORTHSTAR trial of oral gildeuretinol for Stargardt disease, a condition with no approved treatments.

Finding satisfaction in ocular research—considerations about AI and enhanced datasets.

A newly developed diagnostic system, CaptureTumor (CaT), driven by artificial intelligence (AI) and designed specifically for smartphone deployment, achieved diagnostic accuracy comparable to that of a specialist-graded slit-lamp evaluation” for detecting rare ocular surface malignancies.

Guidance includes building on existing science, reducing redundant testing, and accelerating treatments for rare and life-threatening diseases

Two cases illustrate how recognizing and treating Demodex can change surgical outcomes and resolve chronic dry eye disease.

Knowing pregnancy-related risks enhances patient safety.

Michigan pediatric ophthalmologist advances childhood glaucoma care with longer-lasting Ahmed valves, Ologen, and new clues on prematurity glaucoma.

Transient vision loss may foreshadow stroke or heart events; study urges urgent 90-day evaluation and long-term cardiovascular monitoring.

Three cases illustrate how earlier, proactive intervention can reduce medication burden and preserve vision across a range of glaucoma severity.

Investigators noted the patient's symptoms "reliably abated when she played the oboe or when she sang, only to return immediately after stopping.”

Danish JAMA Dermatology trials show short-term topical or oral corticosteroids don’t raise intraocular pressure, easing glaucoma worries in atopic dermatitis care.

New Turkish study links sleeve gastrectomy weight loss to clearer cornea and lens, lower eye pressure, and widened anterior chamber in 6 months.

Wireless brain implant taps visual cortex to deliver artificial sight, marking third successful surgery and recruiting volunteers for trials.

Learn how IBD affects gut and beyond—risk factors, gender differences, eye complications, and treatment options to manage flares and protect vision.

2026 marks 50 years of play.

Phase 3 data show subcutaneous elegrobart quickly reduces proptosis and diplopia in chronic thyroid eye disease, with convenient at-home dosing.

Research suggests that one drop of atropine is all it takes for beneficial effects.

Diastolic perfusion pressure emerges as the strongest predictor of myocardial strain in a recent study.

ECG-synchronized Doppler holography provides repeatable measurements of the retinal blood flow

Melding ophthalmology and neurology

New expert‑led series explores how ophthalmic innovations move from early development to market‑ready therapies through cross‑functional collaboration.

Phase 3 data show brolucizumab outperforms laser for PDR vision preservation, with fewer adverse events—while monitoring inflammation risk.

Mt. Sinai to introduce the miDOC system at the ASCRS annual meeting

The phase 3 study was a randomized, double-masked, placebo-controlled, multicenter trial evaluating subcutaneous teprotumumab administered every 2 weeks for 24 weeks.

Five-year pediatric Boston KPro results show vision gains, but low retention and high membrane, melt and glaucoma risks persist.